The Glivec calculus: what changed after the hype

Hyperbolists think that the decision of the Indian Supreme Court to reject Novartis' Glivec (imatinib mesylate) patent claim has changed the face of the pharma market in India and perhaps in other emerging pharma nations, too. But calmer calculus makes it clear that everything is not quite that dramatic. Sure, India and other BRIC nations are not going to align their intellectual property fully with the West. But that does not mean that incremental innovation is fruitless, or that emerging markets are solely price-driven, or that multinationals will rethink investment in emerging nations. Scrip looks beyond the hyperbole at some of the key messages from the landmark verdict.

Hyperbolists think that the decision of the Indian Supreme Court to reject Novartis' Glivec (imatinib mesylate) patent claim has changed the face of the pharma market in India and perhaps in other emerging pharma nations, too. But calmer calculus makes it clear that everything is not quite that dramatic. Sure, India and other BRIC nations are not going to align their intellectual property fully with the West. But that does not mean that incremental innovation is fruitless, or that emerging markets are solely price-driven, or that multinationals will rethink investment in emerging nations. Scrip looks beyond the hyperbole at some of the key messages from the landmark verdict.

The Supreme Court ruled that the incremental innovations outlined in Novartis’ later Glivec patents [the beta crystalline form of imatinib...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Focus On Asia

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

More from Scrip